Clinical trials: Digestive System Cancer
Esophageal Neoplasms, Esophagectomy
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be…
- Conditions
- Esophageal Neoplasms, Esophagectomy, Brain Metastases
- Trial name
- METABREC (NCT04654975)
- Testing
- Esophagectomy for esophageal cancer
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 10,000 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pancreatic Cancer, Advanced Cancer
LY3214996 +/- HCQ in Pancreatic Cancer
This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.
- Trial name
- NCT04386057
- Testing
- Hydroxychloroquine Sulfate, LY3214996
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kimberly Perez, MD
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Gastrointestinal Stromal Tumors
Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study
This is a prospective, multicenter, observational real-world study to explore the second-line Pharmacotherapy patterns and clinical outcomes in GIST patients who progressed on or were intolerant to first-line anticancer treatment.
- Trial name
- NCT05440357
- Where
- 8 sites in China
- Volunteers
- 100 people
- Sponsor
- Xinhua Zhang, MD
Colorectal Cancer
WT1 in Colorectal Adenocarcinoma
Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors.
- Trial name
- NCT07778628
- Testing
- immunohistochemical staining with WT1 antibody
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Colon Cancer
Response to Immunotherapy in MMR-deficient Localized Colon Cancer
The aim of this study is to evaluate the safety and efficacy of neoadjuvant treatment with pembrolizumab before colonic resection in patients with early-stage (I-III) deficient mismatch repair (dMMR) colon cancer (CC).
- Trial name
- RESET-C (NCT05662527)
- Testing
- Pembrolizumab
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- Camilla Qvortrup
Hepatocellular Carcinoma, Cirrhosis
Estimation of Functional Liver Reserve Using Cholinesterases
Estimation of functional liver reserve in patients with hepatocellular carcinoma (HCC) in cirrhosis is of paramount importance to properly select candidates for surgical resection.
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Liver Neoplasm, Liver Disease
- Trial name
- NCT00883454
- Where
- Italy
- Volunteers
- 181 people
- Sponsor
- University of Milan
Hepatocellular Carcinoma
Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma
The hope to treat more patients with hepatocellular carcinoma successfully is however tempered by the shortage of donors leading to an increasing waiting time for liver transplantation (LT).
- Trial name
- CATCH (NCT01676194)
- Testing
- Intra-arterial administration of DC BeadsR
- Where
- 7 sites in France
- Volunteers
- 7 people
- Sponsor
- Rennes University Hospital
Stomach Cancer, Stomach Neoplasm
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
The primary objective is to evaluate six months survival rate and quality of life at 4 months of ramucirumab alone or in combination with paclitaxel in patients aged 70 years or more who have stomach or GEJ adenocarcinoma and…
- Conditions
- Stomach Cancer, Stomach Neoplasm, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- SOCRATE (NCT03760822)
- Testing
- Ramucirumab, Paclitaxel
- Where
- 38 sites in France
- Volunteers
- 112 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatocellular Carcinoma
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.
- Trial name
- TheraSphere (NCT00683631)
- Testing
- TheraSphere HUD
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of Louisville
Colon Cancer, PCSK9 Inhibitor
Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally…
- Conditions
- Colon Cancer, PCSK9 Inhibitor, Neoadjuvant Immunochemotherapy
- Trial name
- TRIUNITE-08 (NCT07840677)
- Testing
- Tafolecimab, Sintilimab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Stomach Neoplasms, Stomach Cancer
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
Background: Certain stomach cancers are rare, but they have high mortality rates. Researchers want to learn more about gastric (stomach) tumors.
- Trial name
- NCT03027427
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to find out if giving patients bevacizumab along with the chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival.
- Trial name
- NCT00222469
- Testing
- bevacizumab, gemcitabine, oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Nutrition Disorders
Enhanced Recovery After Surgery(ERAS) for Gastric Cancer and Perioperative Nutritional Status
This study is a prospective, single-center, randomized controlled trial. The study protocol was approved by the Ethics Committee at the First Hospital of Jilin University.The perioperation nutritional status will be assessed in…
- Trial name
- NCT03043183
- Testing
- perioperational nutrition surpport
- Volunteers
- 1,400 people
- Sponsor
- The First Hospital of Jilin University
Solid Tumors, Pancreatic Cancer
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Test the hypothesis that itacitinib (INCB039110) can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.
- Trial name
- NCT01858883
- Testing
- itacitinib, Gemcitabine, nab-paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Incyte Corporation
Pediatric Cancer, Solid Tumors
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
This study is looking to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lyso-thermosensitive liposomal doxorubicin (LTLD) administered in combination with MR-HIFU in children with…
- Conditions
- Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT02536183
- Testing
- Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- AeRang Kim
Pancreas Cancer, Pancreatic Cancer
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen peptide vaccine strategy in pancreatic cancer patients following surgical resection and adjuvant chemotherapy.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
- Trial name
- NCT03956056
- Testing
- Neoantigen Peptide Vaccine, Poly ICLC, Blood for immune monitoring
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine
Metastatic Pancreatic Cancer
Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer
The purpose of the study is to evaluate the efficacy of the combination of gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in patients with metastatic pancreatic cancer.
- Trial name
- GECA (NCT01303029)
- Testing
- Gemcitabine+erlotinib, Gemcitabine+erlotinib+capecitabine
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Biliary Tract Cancer, Gallbladder Adenocarcinoma
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer
The purposes of this study are to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good and bad) this combination has on patients with cancer of bile duct or…
- Trial name
- NCT00361231
- Testing
- Bevacizumab, Gemcitabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Irritable Colon, Colorectal Cancer
Colon Investigation - Factors Determining Choice of Procedure
Registration of patients referred for colon investigation by barium enema, CT colonography and colonoscopy in two hospitals and one radiology centre in Telemark, Norway, for a period of minimum six months.
- Conditions
- Irritable Colon, Colorectal Cancer, Inflammatory Bowel Disease
- Trial name
- NCT00423345
- Where
- 3 sites in Norway
- Volunteers
- 750 people
- Sponsor
- Sykehuset Telemark
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.